Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gastric Cancer Treatment: T-DXd

November 3rd 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

FDA Approves Pembrolizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

November 1st 2023

The FDA has approved pembrolizumab (Keytruda) plus gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.

FDA Lifts Clinical Hold on Phase 1 Trial Evaluating XMT-2056 in HER2-Expressing Solid Tumors

October 31st 2023

The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.

Expanding Immunotherapy Armamentarium Propels Personalized HCC Treatment Approaches

October 28th 2023

Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the importance of assessing patients for high-risk disease criteria before beginning any systemic treatment.

Dr Janjigian on Pembrolizumab/Trastuzumab/Chemotherapy in HER2+ Gastric Cancer

October 28th 2023

Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.

Management of ADC Toxicities in Lung Cancer

October 27th 2023

A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.

Antibody-Drug Conjugates in Lung Cancer

October 27th 2023

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Lenvatinib/Pembrolizumab/Chemo Is Safe With Early Efficacy Signals in mESCC

October 23rd 2023

The combination of lenvatinib, pembrolizumab, and chemotherapy had a manageable safety profile and elicited preliminary antitumor activity in patients with metastatic esophageal squamous cell carcinoma.

Gathering Insights in Gastrointestinal Cancers From ESMO 2023: Dr Pietrantonio

October 22nd 2023

Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer

October 20th 2023

The addition of pembrolizumab to combination of trastuzumab and chemotherapy led to an improvement in progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction cancer, particularly in those whose tumors had a PD-L1 combined positive score.

Durvalumab Plus Chemotherapy Elicits pCR Improvement in Resectable Gastric/GEJ Cancer

October 20th 2023

The addition of durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel produced statistically significant and clinically meaningful improvements in pathological complete response rates vs placebo plus FLOT in patients with resectable gastric cancer or gastroesophageal junction cancer.

Toxicity Management for T-DM1 and T-DXd in Breast Cancer

October 20th 2023

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

Antibody-Drug Conjugates in Breast Cancer

October 20th 2023

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

Luminary Awards Highlight Exemplary Work of Experts in GI Cancers

October 18th 2023

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, have announced the winners of the 2023 Luminary Award in GI cancers.

EMA Grants Orphan Drug Designation to LSTA1 for Pancreatic Cancer

October 17th 2023

The European Medicines Agency’s Committee for Orphan Medical Products has granted orphan drug designation to LSTA1 for the treatment of patients with pancreatic cancer.

CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma

October 13th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Best Practices for Patient Education Surrounding Cancer Treatment

October 13th 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Molecular Testing Considerations in Cancer Treatment

October 13th 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Dr Feun on the Evolving Treatment Paradigm in HCC

October 13th 2023

Lynn G. Feun, MD, discusses the evolution of treatment approaches in hepatoceullar carcinoma, the influence of immunotherapies on patient outcomes in this armamentarium, and ongoing avenues of investigation within in the field of HCC management.